XOMA data extremely encouraging, says Roth Capital Roth Capital believes that data for XOMA's anti-IL-1b antibody gevokizumab in pyoderma gangrenosum was "extremely encouraging." The firm expects investors' appreciation for the company to increase as its antibody platform develops, and it keeps a Buy rating on the stock.
XOMA raises $40M in a registered direct offering XOMA (XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. Cowen and Company is acting as the sole placement agent.